Von Hippel-Lindau Disease Epidemiology Forecast 2025-2034

Von Hippel-Lindau disease causes a significant healthcare burden in the United States, with a prevalence of 1.12 per 100,000 for CNS hemangioblastomas and 0.12 per 100,000 for pancreatic tumors in 2019.

Von Hippel-Lindau Disease Epidemiology Forecast Report Coverage

Expert Market Research's “Von Hippel-Lindau Disease Epidemiology Forecast Report 2025-2034” offers comprehensive information on the prevalence and demographics of Von Hippel-Lindau disease. It projects the future incidence and prevalence rates of Von Hippel-Lindau disease cases across various populations. The study covers age, gender, and type as major determinants of the Von Hippel-Lindau disease population. The report highlights patterns in the prevalence of Von Hippel-Lindau disease over time and projects future trends based on multiple variables.

The report provides a comprehensive overview of the disease, as well as historical and projected data on Von Hippel-Lindau disease epidemiology in the 8 major markets.

Regions Covered

• The United States
• Germany
• France
• Italy
• Spain
• The United Kingdom
• Japan
• India

Von Hippel-Lindau Disease Understanding: Disease Overview

Von Hippel-Lindau (VHL) disease is a rare autosomal dominant genetic disorder caused by mutations in the VHL tumor suppressor gene. It leads to the development of benign and malignant tumors in multiple organs, including hemangioblastomas of the brain and retina, renal cysts, renal cell carcinoma, pheochromocytomas, and pancreatic neuroendocrine tumors. Manifesting usually in early adulthood, it requires lifelong surveillance as tumor growth and progression vary widely. Early diagnosis and monitoring are critical for managing complications and improving patient outcomes.

Von Hippel-Lindau Disease Epidemiology Perspective

The Von Hippel-Lindau disease epidemiology division offers information on the patient pool from history to the present, as well as the projected trend for each of the 8 major markets. Expert Market Research provides both current and predicted trends for the Von Hippel-Lindau disease epidemiology scenario by examining a wide range of studies. Additionally, the report covers the diagnosed patient pool for Von Hippel-Lindau disease and its trends. The Von Hippel-Lindau disease detailed epidemiology segmentation is broken down into specific categories, such as total prevalent cases in males and females, and total diagnosed cases across different age groups and patient pools.

• Von Hippel-Lindau disease affects approximately 1.1 to 2.1 individuals per 100,000 worldwide, with an estimated incidence ranging from 1 in 27,000 to 1 in 36,000 live births globally.
• The average age at diagnosis is between 26 and 30 years, with clinical manifestations ranging from childhood through late adulthood, depending on tumor type and genetic mutation variations.
• Epidemiological studies demonstrate no significant difference in VHL disease prevalence or incidence between males and females, indicating equal gender susceptibility.

Country-wise Von Hippel-Lindau Disease Epidemiology Segment

The Von Hippel-Lindau disease epidemiology data and findings for the United States, Germany, Spain, Italy, France, the United Kingdom, Japan, and India are also provided in the epidemiology section.

The epidemiology of Von Hippel-Lindau (VHL) disease highlights a rare but significant genetic tumor predisposition syndrome. In the United States, the prevalence of VHL disease was estimated at 2.13 cases per 100,000 individuals in 2019, with approximately 3,678 patients affected by VHL-associated central nervous system hemangioblastomas and 389 patients with pancreatic neuroendocrine tumors. In Japan, recent population-based data indicate a similar prevalence of about 1.68 cases per 100,000, acknowledging potential underdiagnoses. These findings emphasize the need for improved awareness, early detection, and multidisciplinary management to mitigate disease burden globally.

Von Hippel-Lindau Disease: Treatment Overview

Treatment for Von Hippel-Lindau disease focuses on managing individual tumors and preventing complications. Approaches include surgical removal of symptomatic or high-risk tumors, targeted therapies for renal cell carcinoma, and radiotherapy for central nervous system hemangioblastomas. Regular imaging and clinical surveillance are essential to detect new lesions early. Emerging treatments such as anti-angiogenic agents show promise. Multidisciplinary care involving genetics, oncology, neurosurgery, and ophthalmology optimizes outcomes and quality of life for affected individuals.

Key Questions Answered

• What are the key findings of Von Hippel-Lindau disease epidemiology in the 8 major markets?
• What will be the total number of patients with Von Hippel-Lindau disease across the 8 major markets during the forecast period?
• What was the country-wise Von Hippel-Lindau disease epidemiology scenario in the 8 major markets in the historical period?
• Which country will have the highest number of Von Hippel-Lindau disease during the forecast period of 2025-2034?
• Which key factors would influence the shift in the patient population of Von Hippel-Lindau disease during the forecast period of 2025-2034?
• What are the currently available treatments for Von Hippel-Lindau disease?
• What are the disease risks, signs, symptoms, and unmet needs of Von Hippel-Lindau disease?

Scope of the Von Hippel-Lindau Disease Epidemiology Report

• The report covers a detailed analysis of signs and symptoms, causes, risk factors, pathophysiology, diagnosis, treatment options, and classification/types of Von Hippel-Lindau disease based on several factors.
• Von Hippel-Lindau Disease Epidemiology Forecast Report covers data for the eight major markets (the US, France, Germany, Italy, Spain, the UK, Japan, and India).
• The Von Hippel-Lindau disease report helps to identify the patient population, and the unmet needs are highlighted along with an assessment of the disease's risk and burden.

This product will be delivered within 3-5 business days.